表紙
市場調査レポート

世界および米国の癌バイオマーカー市場予測:特定、技術、市場分析、競合企業プロファイル、コンパニオン診断競合開発、事業戦略、産業動向およびパイプライン分析

GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)

発行 Kelly Scientific Publications 商品コード 299700
出版日 ページ情報 英文 232 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界および米国の癌バイオマーカー市場予測:特定、技術、市場分析、競合企業プロファイル、コンパニオン診断競合開発、事業戦略、産業動向およびパイプライン分析 GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)
出版日: 2014年05月01日 ページ情報: 英文 232 Pages
概要

当レポートでは、癌バイオマーカーおよびコンパニオン診断市場を促進する現在の技術について調査し、現在、医療・製薬産業で用いられている遺伝子診断検査・コンパニオン診断アッセイの調査、個別化医療・薬理ゲノム学改革における発展、世界・米国市場における新しい動向、全体的なバイオマーカー市場・癌バイオマーカー分野のデータ、および将来の成長率予測などを提供しており、主要企業・製品のプロファイルをまとめ、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 世界的な癌の負担

  • 世界の癌統計
  • 世界の肺癌
  • 世界の肺癌変異分析
  • 世界の結腸直腸癌
  • 世界の前立腺癌
  • 世界の乳癌
  • 癌の世界経済への影響
  • 米国における癌
  • 米国における乳癌
  • 米国における肺癌
  • 米国における結腸直腸癌
  • 米国における前立腺癌
  • 米国における皮膚癌

第3章 発がん性バイオマーカー

  • 臨床評価のためのバイオマーカーディスカバリー
  • バイオマーカーディスカバリーに用いられる特定の技術
  • 糖鎖生物学
  • 代謝学(メタボロミクス)
  • ペプチドミクス
  • 主な(マルチ)反応モニタリング
  • DNAに基づいた技術

第4章 バイオマーカー評価

  • イントロダクション
  • バイオマーカー評価の段階
  • バイオマーカー評価・治験

第5章 現在・将来の発がん性バイオマーカー

  • COSMIC (Catalogue of Somatic Mutations in Cancer)
  • P53転写因子発がん性変異
  • EGFR(上皮成長因子受容体)
  • BRCA - 変異がん
  • PARP - 阻害物質の回復
  • PTEN - パイプライン発がん性バイオマーカーにおける現在のリーダー
  • ATM(血管拡張性失調症変異):パイプライン標的
  • TMPRSS2-ERG - 有望な前立腺癌バイオマーカー
  • MiR-17/92 クラスター:バイオマーカーの可能性を持つOncomir

第6章 癌バイオマーカー検査市場分析

  • 世界における癌の経済的負担
  • 米国における癌の経済的負担
  • 世界のバイオマーカー検査市場分析
  • 発がん性バイオマーカーがバイオマーカー市場で支配的
  • 世界のがんプロファイリング技術市場
  • 世界のがんバイオマーカー市場分析
  • バイオマーカー市場全体における癌市場の市場シェア
  • 米国の癌バイオマーカー市場
  • 癌バイオマーカー市場は研究出版物の前年比増によって刺激を受ける
  • プロテオミクスおよびゲノム技術はエンドユーザーから検出手法として好まれる

第7章 癌バイオマーカー市場の主要企業

第8章 癌バイオマーカー市場の製品・キット

第9章 市場参入企業の金融・ビジネス戦略分析

第10章 癌バイオマーカー市場の対象ビジネス・戦略的分析

  • 癌バイオマーカー市場の促進因子
  • 癌バイオマーカー市場の課題
  • 癌バイオマーカー市場の抑制因子
  • 癌バイオマーカー市場の機会

図表リスト

目次
Product Code: KSPCBM

“GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)” by Kelly Scientific Publications is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment.

Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.

One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics.

Table of Contents

1.0. Executive Summary

  • 1.1. Objectives of Report
  • 1.2. Data Sources and Methodology
  • 1.3. Key Findings and Observations
    • 1.3.1. What Makes Cancer Biomarkers so Important for the Healthcare Industry?
    • 1.3.2. What Technologies are Used to Identify Novel Biomarkers?
    • 1.3.3. Increase in Cancer Prevalence is Propelling the Oncogenic Biomarker Market
    • 1.3.4. Global and US Economic Impact of Cancer
    • 1.3.5. How Cancer Biomarkers are Revolutionizing Cancer Treatment
    • 1.3.6. What are the most Significant and Strategic Cancer Biomarkers?
    • 1.3.7. Global Biomarker Test Market Analysis
    • 1.3.8. Global Cancer Biomarker Market Analysis
    • 1.3.9. Oncology Biomarker Market Main Industry Players
    • 1.3.10. Drivers, Restraints, Opportunities and Challenges of the Cancer Biomarker Market

2.0. Global Burden of Cancer

  • 2.1. Global Cancer Statistics
  • 2.2. Lung Cancer Globally
  • 2.3. Lung Cancer Mutation Analysis
  • 2.4. Colorectal (Bowel) Cancer Globally
  • 2.5. Prostate Cancer Globally
  • 2.6. Breast Cancer Globally
  • 2.7. Global Economic Impact of Cancer
  • 2.8. Cancer in the USA
  • 2.9. Breast Cancer in the US
  • 2.10. Lung Cancer in the US
  • 2.11. Colorectal Cancer in the US
  • 2.12. Prostate Cancer in the US
  • 2.13. Skin Cancer in the US

3.0. Oncogenic Biomarkers - An Overview

  • 3.1. Biomarker Discovery to Clinical Validation
  • 3.2. Specific Technologies Used in Biomarker Discovery
    • 3.2.1. Proteomics
    • 3.2.2. Mass Spectrometry Based Technologies
    • 3.2.3. Principles of Diagnostic Mass Spectrometry
    • 3.2.4. Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
    • 3.2.5. Nano LC-MS/MS
    • 3.2.6. MALDI-TOF
  • 3.3. Glycomics
  • 3.4. Metabolomics
  • 3.5. Peptidomics
    • 3.5.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 3.6. Selected (Multiple) Reaction Monitoring
  • 3.7. DNA Based Techniques
    • 3.7.1. Microarrays
    • 3.7.2. Small Molecule Real Time (SMRT) DNA Sequencing
    • 3.7.3. Digital PCR
    • 3.7.4. Next Generation Sequencing
    • 3.7.5. Second-Generation Sequencing Platforms
    • 3.7.6. Whole Genome Sequencing
    • 3.7.7. Epigenomics
    • 3.7.8. Bioinformatics and Next Generation Sequencing
    • 3.7.9. Third Generation Sequencing

4.0. Biomarker Validation

  • 4.1. Introduction
  • 4.2. Phases of Biomarker Validation
  • 4.3. Biomarker Validation and Clinical Trials

5.0. Current and Prospective Oncogenic Biomarkers

  • 5.1. Catalogue of Somatic Mutations in Cancer (COSMIC)
  • 5.2. P53 Transcription Factor Oncogenic Mutations
    • 5.2.1. Current Clinical Trials Investigating P53 as an Oncogenic Biomarker
  • 5.3. Epidermal Growth Factor Receptor (EGFR)
    • 5.3.1. EGFR-Activating and Resistance Mutations
    • 5.3.2. Clinically Validated Resistance Mechanisms to EGFR Inhibitors
    • 5.3.3. Current Strategies to Defeat Resistance to EGFR-Mediated Cancer Therapeutics
  • 5.4. BRCA- Mutant Cancers
  • 5.5. PARP-Inhibitors are Making a Comeback
    • 5.5.1. Olaparib - A Pipeline PARP-Inhibitor
    • 5.5.2. Niraparib (MK4827) in Phase III trials
    • 5.5.3. Rucaparib
    • 5.5.4. Veliparib
    • 5.5.5. Novel Biomarkers in the PARP-Inhibitor Response Pathway
  • 5.6. PTEN - Current Leader in Pipeline Onocogenic Biomarkers
  • 5.7. Ataxia Telangiectasia Mutated (ATM) - A Pipeline Target
  • 5.8. TMPRSS2-ERG - A Promising Prostate Cancer Biomarker
  • 5.9. MiR-17/92 Cluster - The Oncomir with Biomarker Potential
    • 5.9.1. Altered MiR-17/92 Expression Correlates with Cancer Pathogenesis
    • 5.9.2. MiR-17/92 Cluster and Colorectal Cancer
    • 5.9.3. MiR-17/92 Cluster and Breast Cancer
    • 5.9.4. MiR-17/92 Cluster and Ovarian Cancer
    • 5.9.5. MiR-17/92 Cluster and Lung Cancer
    • 5.9.6. MiR-17/92 Cluster and Renal Cancer
    • 5.9.7. MiR-17/92 Cluster and Head and Neck Cancer
    • 5.9.8. MiR-17/92 Cluster and Pancreatic Cancer
    • 5.9.9. MiR-17/92 Cluster and Liver Cancer
    • 5.9.10. MiR-17/92 Cluster and Acute Myeloid Leukaemia
    • 5.9.11. MiR-17/92 Cluster and B-Cell Lymphoma
    • 5.9.12. MiR-17/92 Cluster and B-Cell Chronic Lymphocytic Leukemia
    • 5.9.13. Transcriptional Regulators of MiR-17/92 Cluster
    • 5.9.14. Significant Molecular Targets of MiR-17/92

6.0. Cancer Biomarker Test Market Analysis 2013-2018

  • 6.1. Economic Burden of Cancer Worldwide
  • 6.2. Economic Burden of Cancer in the US
  • 6.3. Global Biomarker Test Market Analysis
  • 6.4. Oncology Biomarkers Dominate the Biomarker Market
  • 6.5. Global Cancer Profiling Technology Market
  • 6.6. Global Cancer Biomarker Market Analysis
  • 6.7. Market Share of Oncology Market Within Total Biomarker Market
  • 6.8. US Cancer Biomarker Market
  • 6.9. Oncology Biomarker Market is Fuelled by Year-on-Year Expansion of Research Publications
  • 6.10. Proteomic and Genomic Technologies are Preferred as Methods of Detection by End-Users

7.0 Oncology Biomarker Market Main Industry Players

  • 7.1. 23andMe
  • 7.2. Affymetrix
  • 7.3. Ambry Genetics
  • 7.4. Astex Pharmaceuticals
  • 7.5. Atossa Genetics
  • 7.6. CuraGen
  • 7.7. Celera Corporation (Quest Diagnostics)
  • 7.8. Celldex Therapeutics
  • 7.9. deCode Genetics (Amgen)
  • 7.10. Foundation Medicine
  • 7.11. Illumina
  • 7.12. Genelex
  • 7.13. Genomic Health
  • 7.14. Myriad
  • 7.15. Nodality
  • 7.16. OriGene Technologies
  • 7.17. Randox
  • 7.18. Qiagen

8.0. Oncology Biomarker Market Products and Kits

  • 8.1. Oncology Companion Diagnostic Tests
    • 8.1.1. HER2 Tests in Breast Cancer Patients
  • 8.2. 23andMe
  • 8.3. Affymetrix
  • 8.4. Ambry Genetics
    • 8.4.1. BRCAPlus
    • 8.4.2. BreastNext
    • 8.4.3. CancerNext
    • 8.4.4. ColoNext
    • 8.4.5. OvaNext
    • 8.4.6. PancNext
    • 8.4.7. RenalNext
    • 8.4.8. Hereditary Diffuse Gastric Cancer Test
  • 8.5. Astex Pharmaceuticals
  • 8.6. Atossa Genetics
    • 8.6.1. Mammary Aspirate Specimen Cytology Test (MASCT™)
    • 8.6.2. ForeCYTE Breast Health Test (SM)
    • 8.6.3. ArgusCYTE Breast Health Test(SM)
    • 8.6.4. FullCYTE Breast Health Test
    • 8.6.5. NextCYTE Breast Health Test
  • 8.7. BioMerieux
    • 8.7.1. THxID™ -BRAF Kit
  • 8.8. Celera (Quest Diagnostics)
  • 8.9. deCode Genetics
    • 8.9.1. deCODE Breast Cancer™
    • 8.9.2. deCODE Prostate Cancer™
    • 8.9.3. deCODE AF™
    • 8.9.4. deCODE Complete™
    • 8.9.5. deCODE Cancer™
    • 8.9.6. deCODE Services
  • 8.10. Foundation Medicine
    • 8.10.1. FoundationOne
    • 8.10.2. FoundationOne Heme
  • 8.11. Illumina
    • 8.11.1. Illumina New-Generation Sequencing Technology
    • 8.11.2. Illumina HiSeq 2500/1500
    • 8.11.3. Illumina HiSeq 2000/1000
    • 8.11.4. Genome Analyzer IIx
    • 8.11.5. Illumina MiSeq
    • 8.11.6. Illumina HiScanHQ
    • 8.11.7. Illumina HiScan and iScan Array
  • 8.12. Genelex
  • 8.13. Genomic Health
    • 8.13.1. Oncotype DX Breast Cancer Test
    • 8.13.2. Oncotype DX Colon Cancer Test
    • 8.13.3. Oncotype DX Prostate Cancer Assay
  • 8.14. Myriad Genetics
    • 8.14.1. BRACAnalysis®
    • 8.14.2. Comprehensive BRACAnalysis®
    • 8.14.3. BRACAnalysis® Rearrangement Test (BART)
    • 8.14.4. Single Site BRACAnalysis®
    • 8.14.5 Multisite 3 BRACAnalysis®
    • 8.14.6. COLARIS®/COLARIS AP®
    • 8.14.7. MELARIS®
    • 8.14.8. PANEXIA®
    • 8.14.9. OnDose®
    • 8.14.10. PREZEON™
    • 8.14.11. THERAGUIDE® 5FU
    • 8.14.12. Prolaris®
  • 8.15. Nodility
  • 8.16. OriGene
    • 8.16.1. TissueScan™ Cancer cDNA Arrays
  • 8.17. Randox
    • 8.17.1. Tumor PSA Marker Array
    • 8.17.2. Tumor Marker Array 3
    • 8.17.3. KRAS/ BRAF/PIK3CA Array
  • 8.18. Qiagen
    • 8.18.1. Genotyping Products
    • 8.18.2. QIAsymphony Platform
    • 8.18.3. Therascreen® EGFR RGQ PCR Kit
    • 8.18.4. Therascreen KRAS RGQ PCR System
    • 8.18.5. Therascreen® IDH1/2 test
  • 8.19. Roche
    • 8.19.1. Cobas® EGFR Mutation Test

9.0. Market Participant Financial and Business Strategy Analysis

  • 9.1. 23andMe
  • 9.2. Affymetrix
  • 9.3. Astex Pharmaceuticals (Otuska Pharamceutical)
  • 9.4. Atossa Genetics
  • 9.5. BioMerieux
  • 9.6. Celera (Quest Diagnostics)
  • 9.7. Celldex Therapeutics
  • 9.8. deCode Genetics (Amgen)
  • 9.9. Foundation Medicine
  • 9.10. Illumina
  • 9.11. Genelex
  • 9.12. Genomic Health
  • 9.13. Myriad
  • 9.14. Nodality
  • 9.15. Qiagen

10.0. Objective Business and Strategic Analysis of the Cancer Biomarker Market

  • 10.1. Drivers of Oncogenic Biomarker Market
    • 10.1.1. High demand and Unmet Need Enhances the Global Biomarker Market
    • 10.1.2. Biomarkers are Highly Specific Diagnostic and Prognostic Clinical Tools
    • 10.1.3. Increasing Cancer Prevalence Globally
    • 10.1.4. FDA Support Increases Biomarker Development
    • 10.1.5. More Streamlined Clinical Trials
    • 10.1.6. Significant Growth of High-Impact Oncogenic Biomarker Research
    • 10.1.7. Advancements in Discovery Technologies
  • 10.2. Challenges of the Oncogenic Biomarker Market
    • 10.2.1. Variability of Biomarkers within Different Cancer Subtypes
    • 10.2.2. Integration of Genomics and Biomarker Diagnostics into the Healthcare System
    • 10.2.3. Ethical Considerations
  • 10.3. Restraints of the Cancer Biomarker Market
    • 10.3.1. Initial Investment into Biomarker Discovery and Development
    • 10.3.2. Are Biomarkers Profitable for Smaller Companies?
  • 10.4. Opportunities for the Cancer Biomarker Market
    • 10.4.1. Personalized Medicine Market Opportunities
    • 10.4.2. Companion Diagnostics

List of Figures

  • Figure 2.1: Global Cancer Statistics - Key Facts
  • Figure 2.2: Number of Lung, Breast and Colorectal Cancer Diagnoses Globally, 2012
  • Figure 2.3: Percentage of Lung, Breast and Colorectal Cancer Diagnoses Globally, 2012
  • Figure 2.4: Number of Lung, Liver and Stomach Cancer Deaths Globally, 2012
  • Figure 2.5: Percentage of Lung, Liver and Stomach Cancer Deaths Globally, 2012
  • Figure 2.6: Global Cancer Incidence, Men 2012 (per 100,000)
  • Figure 2.7: Global Cancer Mortality, Men 2012 (per 100,000)
  • Figure 2.8: Global Cancer Incidence, Women 2012 (per 100,000)
  • Figure 2.9: Global Cancer Mortality, Women 2012 (per 100,000)
  • Figure 2.10: Number (Millions) of Smokers (Men and Women) in China, Russia, India, the UK and USA
  • Figure 2.11: Incidence and Mortality Rates of Global Lung Cancer (Male and Female)
  • Figure 2.12: Incidence and Mortality Rates of Global Colorectal Cancer (Male and Female)
  • Figure 2.13: Incidence and Mortality Rates of Global Prostate Cancer
  • Figure 2.14: Global Incidence and Mortality of All Cancer Types (excl non-melanoma skin-cancer) per 100,000, Male and Female
  • Figure 2.15: Combined Global Prostate, Breast, Colorectal, Lung and Bladder Cancer Incidence and Mortality by Male and Female
  • Figure 2.16: Cancer Deaths in Women, Globally according to Cancer Type
  • Figure 2.17: Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer Globally
  • Figure 2.18: Top Three Cancers Leading to Global Economic Burden of Cancer ($ Billion)
  • Figure 2.19: Top 20 Cancers in the USA, Adults (Male and Female)
  • Figure 2.20: Top Adult Male Cancers, USA, Estimated Five Year Prevalence 2012-2017
  • Figure 2.21: Top Adult Female Cancers, USA, Estimated Five Year Prevalence 2012-2017
  • Figure 2.22: US Age Adjusted Cancer Death Rates Per 100,000 (Male) by Cancer Type, 1930-2009
  • Figure 2.23: US Age Adjusted Cancer Death Rates Per 100,000 (Female) by Cancer Type, 1930-2009
  • Figure 2.24: Incidence and Mortality of Lung Cancer (Male) Patients in the Americas
  • Figure 2.25: Incidence and Mortality of Lung Cancer (Female) Patients in the Americas
  • Figure 2.26: Incidence and Mortality of Colorectal Cancer (Male and Female) Patients in the Americas
  • Figure 2.27: Colorectal Cancer Incidence Rates (per 100,000) by Race/Ethnicity and Sex, USA
  • Figure 2.28: Colorectal Cancer Death Rates (per 100,000) by Race/Ethnicity and Sex, USA
  • Figure 2.29: Colorectal Cancer Incidence Rates (per 100,000) by State, USA
  • Figure 2.30: Colorectal Cancer Mortality Rates (per 100,000) by State, USA
  • Figure 2.31: Adults Aged 50-75 Years (%) That are Up-to-Date with Colorectal Test Screening, by State, United States
  • Figure 2.32: Incidence and Mortality of Prostate Cancer (Male) Patients in the Americas
  • Figure 2.33: Incidence and Mortality of Melanoma (Male and Female) Patients in the Americas
  • Figure 3.1: Integration of Oncogenic Biomarker Data to Cancer Diagnosis and Clinical Decisions
  • Figure 3.2: Influence of Biomarker Market on R&D, Molecular Diagnostics, Emerging Diagnostics and Independent Clinical Molecular Diagnostic Services
  • Figure 3.3: Biomarker Discovery to Clinical Assay Development and Validation Process
  • Figure 3.4: Mass Spectrometry Based Technologies in Oncogenic Biomarker Discovery
  • Figure 3.5: Principles of Enzyme-Linked Immunosorbant Assay (ELISA)
  • Figure 4.1: The Different Phases of Fit-For-Purpose Biomarker Validation
  • Figure 4.2: Biomarker Validation Using ELISA Technique
  • Figure 5.1: Frequency of Genetic Mutation by Cancer Subtype
  • Figure 5.2: Oncogenic Biomarker P53 Signalling Pathway: Activators, Effectors, Inhibitors and Cellular Outcomes
  • Figure 5.3: P53 Somatic Mutation Prevalence by Tumor Site
  • Figure 5.4: P53 Germline Mutation Prevalence by Tumor Site
  • Figure 5.5: EGFR Signalling Pathways and Potential Biomarker Proteins
  • Figure 5.6: Clinically Validated Resistance Mechanisms to EGFR Inhibitors
  • Figure 5.7: BRCA Mutation Increases the Risk of Breast and Ovarian Cancer
  • Figure 5.8: Proactive Cancer Management and Preventative Measures Reduces the Risks of Developing BRCA-associated Breast and Ovarian Cancer
  • Figure 6.1: Economic Burden of Cancer in the US, Direct and Indirect Costs ($ billion)
  • Figure 6.2: Economic Burden of Cancer in the US, Direct and Indirect Costs (%)
  • Figure 6.3: Global Biomarker Market Worth (Billions) and CAGR (%) 2011-2018
  • Figure 6.4: Oncogenic Biomarker Share of Total Personalized Medicine Biomarker Space
  • Figure 6.5: Oncogenic Biomarker Market Distribution by Cancer Type
  • Figure 6.6: Global Cancer Profiling Technology Market Worth (Billions) and CAGR 2013-2018
  • Figure 6.7: Global Cancer Biomarker Market Worth (Billions) and CAGR (%) 2009-2018
  • Figure 6.8: Global Oncology Biomarker Market as a Percentage of Total Biomarker Market 2013-2018
  • Figure 6.9: USA Cancer Biomarker Market Share Compared to Global Biomarker Market 2013-2018
  • Figure 6.10: Number of Peer-Reviewed Publications in the Area of Oncology Biomarker Research 2008-2013
  • Figure 6.11: Number of Peer-Reviewed Publications ion Oncogenes within Oncogenic Biomarker Research 2008-2013
  • Figure 6.12: Number of Peer-Reviewed Publications on MicroRNAs Within Oncology Biomarker Research 2008-2013
  • Figure 6.13: Number of Peer-Reviewed Publications on Epigenetic Modifications Within Oncology Biomarker Research 2008-2013
  • Figure 6.14: Number of Peer-Reviewed Publications by the National Cancer Institute Within Oncology Biomarker Research 2008-2013
  • Figure 6.15: Number of Peer-Reviewed Publications on Tumor Suppressor Genes Within Oncology Biomarker Research 2008-2013
  • Figure 6.16: Number of Peer-Reviewed Publications on incRNA Within Oncology Biomarker Research 2008-2013
  • Figure 6.17: Most Popular Proteomic and Genomic Technologies Performed by End-Users
  • Figure 7.1: Celldex Therapeutics Product Pipeline
  • Figure 7.2: Single Cell Network Profiling (SCNP) Technology by Nodality
  • Figure 7.3: Developed Functional Assays that Nodality has explored using new SCNP Technology
  • Figure 8.1: HER2 Testing Algorithm for Breast Cancer
  • Figure 8.2: HER2 Cellular Signalling
  • Figure 8.3: QUICKFACTS: Herceptin - Mechanism of Action
  • Figure 8.4: Illumina New Generation Sequencing Technology Workflow Station
  • Figure 8.5: Genomic Health Studies Used in the Development of the DCIS Score Algorithm
  • Figure 8.6: Genomic Health Gene Panel Used for Oncotype DX Breast Cancer Test
  • Figure 8.7: Genomic Health Gene Panel Used for Oncotype DX Colon Cancer Test
  • Figure 8.8: Genomic Health Oncotype DX Prostate Cancer Test Development Process
  • Figure 8.9: Genomic Health Gene Panel Used for Oncotype DX Prostate Cancer Test
  • Figure 8.10: OriGene's TissueScan Cancer cDNA Array Sequence of Analysis
  • Figure 9.1: Private Funding Gained by 23andMe 2007-2012
  • Figure 9.2: Affymetrix Revenue by Business Segment (Percentage), 2013
  • Figure 9.3: Affymetrix Revenue by Business Segment (Percentage), 2013
  • Figure 9.4: Affymetrix Total Revenue 2007-2013
  • Figure 9.5: Affymetrix Revenue by Product Division - Consumables, Instruments 2010-2012
  • Figure 9.6: Affymetrix Core Product Sales - Gene Expression, Genetic Analysis & Clinical Applications and Life Science Reagents, 2011-2012
  • Figure 9.7: Affymetrix Revenue Derived from Outside the US, 2009-2012
  • Figure 9.8: Affymetrix Revenue Derived from the US, 2009-2012
  • Figure 9.9: Affymetrix Net Loss, 2009-2012
  • Figure 9.10: Affymetrix Research and Development Funding, 2009-2012
  • Figure 9.11: Affymetrix Revenue Generated within USA (Percentage) 2010-2012
  • Figure 9.12: Astex Pharmaceuticals Priority Pipeline Products SGI-110 and AT13387 by Indication, Clinical Phase and Timeline
  • Figure 9.13: Astex Pharmaceuticals Revenue Generated 2008-2012
  • Figure 9.14: Astex Pharmaceuticals Net Income 2009-2012
  • Figure 9.15: Atossa Genetics Total Revenue (US$) 2011, 2012
  • Figure 9.16: Atossa Genetics Revenue (US$) Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012
  • Figure 9.17: Atossa Genetics Percentage Revenue Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012
  • Figure 9.18: Quest Diagnostics Revenue ($ Billions) 2008-2013
  • Figure 9.19: Quest Diagnostics Operating Revenue ($ Billions) 2008-2013
  • Figure 9.20: Quest Diagnostics Net Income ($ Billions) 2008-2013
  • Figure 9.21: Celera (Quest Diagnostics) Historic Revenue Generated 2008-2010
  • Figure 9.22: Celera (Quest Diagnostics) Historic Gross Margin Generated 2008-2010
  • Figure 9.23: Celera (Quest Diagnostics) Historic Revenue Generated- Laboratory Services and Products 2008-2010
  • Figure 9.24: Celera (Quest Diagnostics) Historic Revenue (%) Generated by Distribution Agreement with Abbott 2008-2010
  • Figure 9.25: Celera (Quest Diagnostics) Historic Research and Development Spending 2008-2010
  • Figure 9.26: deCode Genetics Historic Net Loss Incurred 2004-2008
  • Figure 9.27: Foundation Medicine International Sales - FoundationOne 2012-2013
  • Figure 9.28: Foundation Medicine International Revenue 2012-2013
  • Figure 9.29: Foundation Medicine Geographical (USA) Revenue Percentage 2011-2013
  • Figure 9.30: Illumina Revenue Generated ($ Billions) 2010-2013
  • Figure 9.31: Illumina Net Income Generated ($ Billions) 2010-2013
  • Figure 9.32: Genomic Health Oncotype DX Test Revenue 2008-2013
  • Figure 9.33: Myriad Revenue Generated 2007-2014
  • Figure 9.34: Operating Income Generated by Myriad 2007-2013
  • Figure 9.35: Myriad Revenue Generated by Molecular Diagnostic Testing and Companion Diagnostic Services, 2012-2013
  • Figure 9.36: Future Molecular Diagnostic Pipeline of Myriad
  • Figure 9.37: Customer Profile of Qiagen - Percentage of Net Sales 2012/2013
  • Figure 9.38: Qiagen Global Net Sales 2007-2013
  • Figure 9.39: Qiagen Operating Income 2007-2013
  • Figure 9.40: Qiagen Global Net Income 2007-2013

List of Tables

  • Table 2.1: QUICKFACTs- Top Five Most Frequent Cancers in Men and Women, Globally
  • Table 2.2: Main Clinical Stages of Lung Cancer
  • Table 2.3: Current Therapeutic Options for Lung Cancer
  • Table 2.4: QUICKFACTs- Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer per Country, Worldwide
  • Table 2.5: Risk Factors of Colorectal Cancer
  • Table 3.1: Important Advantages of Using Biomarkers as Diagnostic Tools
  • Table 3.2: Biomarkers in Early Drug Development and Decision Making
  • Table 3.3: Biomarkers in Later Drug Development and Decision Making
  • Table 3.4: Functions of Biomarkers within the Healthcare Setting
  • Table 3.5: Ideal Attributes of Clinical Oncogenic Biomarkers
  • Table 3.6: Main Technologies Used in the Discovery of Biomarkers
  • Table 3.7: Proteomic Technologies Used in Biomarker Discovery
  • Table 3.8: Types of Cancer Aided Diagnostically by Mass Spectrometry
  • Table 3.9: Recommendations for Use of MALDI-TOF MS in Cancer Diagnostics
  • Table 3.10: Metabolomic Discovered Potential Oncogenic Biomarkers
  • Table 3.11: Cancer Biomarkers in Clinical Practice Using ELISA Technology
  • Table 3.12: Putative Cancer Biomarkers that can be Detected using ELISA Technology
  • Table 3.13: Advantages of Selected (Multiple) Reaction Monitoring Technique in Biomarker Discovery
  • Table 3.14: Major Advantages of Microarray Assays
  • Table 3.15: Applications of Microarrays
  • Table 3.16: Applications of Microarray Technology in Cancer Diagnostics
  • Table 3.17: Commercially Available Microarray Kits for Cancer Diagnostics
  • Table 3.18: Recommendations for Use of Microarrays in Cancer Diagnostics
  • Table 3.19: Digital PCR in Comparison to Real-time PCR and Traditional PCR
  • Table 3.20: Advantages of Digital PCR
  • Table 3.21: Applications of Digital PCR
  • Table 4.1: Current General Classes of Biomarker Assay as Defined by the American Association of Pharmaceutical Scientists
  • Table 4.2: Comparison of Validative Properties of Different Bioassay Classes
  • Table 5.1: Catalogue of Somatic Mutations in Cancer (COSMIC) Current Statistics
  • Table 5.2: Important Genetic Oncogenic Biomarkers and Their Application in Treatment
  • Table 5.3: P53 Somatic Mutation Prevalence by Tumor Site
  • Table 5.4: P53 Germline Mutation Prevalence by Tumor Site
  • Table 5.5: List of P53 Down-regulated Gene Targets
  • Table 5.6: List of P53 Up-regulated Gene Targets
  • Table 5.7: Positive Regulators of Epidermal Growth Factor Receptor (EGFR) Activity
  • Table 5.8: Types of Cancer Associated with EGFR Over-expression
  • Table 5.9: EGFR-Activating and Resistance Mutations Identified in Lung Adenocarcinoma
  • Table 5.10: Current Next Generation EGFR Inhibitors that Target the T790M Mutation
  • Table 5.11: Prevalence of Deleterious Mutations in BRCA1 and BRCA2 Genes
  • Table 5.12: Prevalence of Deleterious Mutations in BRCA1 and BRCA2 in Individuals of Ashkenazi Ancestry
  • Table 5.13: Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC)
  • Table 5.14: PARP Inhibitors in Late-Stage Development
  • Table 5.15: Novel and Potential Biomarkers Within the PARP-Inhibitor Response Pathway
  • Table 5.16: Negative Regulators of PTEN Protein Expression
  • Table 5.17: Positive Regulators of PTEN Protein Expression
  • Table 5.18: ATM Molecular Targets and Protein Interactions
  • Table 5.19: Key Facts Regarding MiR-17/92 Cluster
  • Table 5.20: Expression Levels of Individual MiR-17/92 Biomarkers in Cancer, Cardiovascular Disease, Alzheimer's, Multiple Sclerosis, Aging and Normal Development
  • Table 5.21: Functional and Validated Positive Regulators of MiR-17/92
  • Table 5.22: Functional and Validated Negative Regulators of MiR-17/92
  • Table 5.23: Potential Regulators of MiR-17/92
  • Table 5.24: Cellular Signal Transduction Pathways Regulated by the MiR-17/92 Cluster
  • Table 5.25: Specific Cell Death Protein Targets of the MiR-17/92 Cluster
  • Table 5.26: Specific Cell Cycle Arrest Protein Targets of the MiR-17/92 Cluster
  • Table 5.27: Specific Cell Cycle Regulation Protein Targets of the MiR-17/92 Cluster
  • Table 5.28: Specific Heart and Lung Development Protein Targets of the MiR-17/92 Cluster
  • Table 5.29: Specific Cell Proliferation Protein Targets of the MiR-17/92 Cluster
  • Table 6.1: Global Biomarker Market Worth (Billions) and CAGR (%) 2011-2018
  • Table 6.2: Main Diagnostic Areas Within Oncology Biomarker Market
  • Table 6.3: Future Diagnostic Areas With High Potential Within Oncology Biomarker Market
  • Table 6.4: Global Cancer Profiling Technology Market Worth (Billions) and CAGR 2013-2018
  • Table 6.5: Global Cancer Biomarker Market Worth (Billions) and CAGR (%) 2009-2018
  • Table 6.6: USA Cancer Biomarker Market Share Compared to Global Biomarker Market 2013-2018
  • Table 6.7: Main Sub-Sets of Oncogenic Biomarker Research Published 2008-2013
  • Table 7.1: Patent Listing of Affymetrix Array technology
  • Table 7.2: Patent Listing of Affymetrix Genotyping Technology
  • Table 7.3: Patent Listing of Affymetrix Expression and Profiling Technology
  • Table 7.4: Advantages of Astex Pharmaceuticals Pyramid™ Fragment-Drug-Discovery System
  • Table 7.5: Astex Pharmaceuticals Pipeline Portfolio
  • Table 7.6: Astex Pharmaceuticals Pipeline Portfolio Funded Completely by Partner Companies
  • Table 7.7: Potential Business Partnerships of Celldex Therapeutics
  • Table 7.8: Illumina Core Technologies
  • Table 7.9: Illumina Core Technology Applications
  • Table 7.10: Illumina Instrument Product Portfolio
  • Table 7.11: Illumina Assay Product Portfolio
  • Table 7.12: Genetic Test Panel Available from Genelex for Research Institutions and Clinical Trials
  • Table 7.13: Pre-Clinical, Clinical and Commercial Applications of SCNP by Nodality
  • Table 7.14: Qiagen Timeline of Events, 1994-2012
  • Table 7.15: QUICKFACTs - Range of Product Groups from Qiagen
  • Table 8.1: Types of Diagnostic Tests Available to Determine HER2 Status in Breast Cancer Patients
  • Table 8.2: Validated HER2 Tests for Cancer
  • Table 8.3: Advantages and Limitations of IHC HER2 testing applied to breast cancer
  • Table 8.4: In-Situ Hybridization Determination of HER2 Expression by PathVysion® and HER2 FISH pharmDxTM
  • Table 8.5: HER2 CISH Determination
  • Table 8.7: Validated FISH Kits for HER2 Testing in Breast Cancer
  • Table 8.8: Validated SISH Kits for HER2 Testing in Breast Cancer
  • Table 8.9: Validated CISH Kits for HER2 Testing in Breast Cancer
  • Table 8.10: Advantages and Limitations of ISH Techniques Applied to HER2 Testing in Breast Cancer
  • Table 8.11: 23andMe Disease Risk Genetic Test Panel
  • Table 8.12: 23andMe Carrier Status Genetic Test Panel
  • Table 8.13: 23andMe Drug Response Genetic Marker Test Panel
  • Table 8.14: 23andMe Genetic Traits Test Panel
  • Table 8.15: QUICKFACTs - Product Overview of Affymetrix
  • Table 8.16: Microarray Products by Affymetrix
  • Table 8.17: Affymetrix Research Services Laboratory (ARSL) Premier Services
  • Table 8.18: Genetic Applications of Axiom® Technology by Affymetrix
  • Table 8.19: Clinical Diagnostic Test Kits Available from Ambry Genetics
  • Table 8.20: Ambry Genetics Cancer Test Portfolio and Genetic Biomarkers
  • Table 8.21: Ambry Genetics Comprehensive List of Genetic Tests by Disease and Genetic Biomarkers
  • Table 8.22: Ambry Genetics BRCA1/2 Breast Cancer Test Portfolio
  • Table 8.23: Ambry Genetics Genome Sequencing Services
  • Table 8.24: Ambry Genetics New Generation Sequencing Platform Portfolio & Applications
  • Table 8.25: Range of Small Molecule Therapeutics Available from Astex Pharmaceuticals
  • Table 8.26: Genetic Tests Available from BHL/Celera
  • Table 8.27: Panel of BHL Clinical Diagnostic Tests
  • Table 8.28: Genetic Diagnostic Tests Available from deCode Genetics
  • Table 8.29: Disease States that are Included in the deCODE Complete™ Genetic Screen
  • Table 8.30: Panel of Diseases Screened for in the deCODE Cancer™ Test
  • Table 8.31: deCODE Genetics Genotyping and Sequencing Service
  • Table 8.32: deCODE Genetics Data Management, Protection and Storage Service
  • Table 8.33: deCODE Genetics Sequence Inputation and Data Analysis Service
  • Table 8.34: FoundationOne Assay Technical Specifications
  • Table 8.35: FoundationOne Assay Oncogenic Gene Portfolio
  • Table 8.36: FoundationOne Heme Assay Oncogenic Gene Portfolio
  • Table 8.37: Illumina HiSeq 2500/1500 Performance Parameters
  • Table 8.38: Illumina HiSeq 2000/1000 Performance Parameters
  • Table 8.39: Genome Analyzer IIx Performance Parameters
  • Table 8.40: Illumina MiSeq Product Specifications
  • Table 8.41: Illumina HiScanHQ Product Specifications
  • Table 8.42: Illumina HiScan and iScan Array Product Applications
  • Table 8.43: Illumina HiScan and iScan Array Kits
  • Table 8.44: Predictive Genetic Tests Available from Myriad
  • Table 8.45: Services offered with BRACAnalysis® Testing from Myriad
  • Table 8.46: Advantages of BRACAnalysis® Testing
  • Table 8.47: QUICK FACTs- Prevalence of Deleterious Mutations in BRCA1 & BRCA2 Genes
  • Table 8.48: QUICK FACTs- prevalence of deleterious mutations in BRCA1 and BRCA2 in individuals of Ashkenazi Ancestry
  • Table 8.49: QUICK FACTs- Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC)
  • Table 8.50: QUICKFACTs- BRACAnalysis® Panel of Assays
  • Table 8.51: COLARIS® Test Range by Myriad
  • Table 8.52: COLARIS AP® Test Range by Myriad
  • Table 8.53: MELARIS® Test Range from Myriad
  • Table 8.54 Personalized Medicine Tests from Myriad
  • Table 8.55: The Prolaris Score for Prostate Cancer
  • Table 8.56: OnDose® Testing Procedure from Myriad
  • Table 8.57: OriGene TissueScan cDNA Array Oncology Product Portfolio
  • Table 8.58: Qiagen Genotyping Products for Sample Collection, stabilization and Storage
  • Table 8.59: Qiagen Genotyping Products for Genomic DNA Isolation and Purification
  • Table 8.60: Qiagen Genotyping Products for PCR Based Genotyping Analysis
  • Table 8.61: Qiagen Products for Genotyping Analysis
  • Table 8.62: Qiagen Genotyping Products for PCR Detection
  • Table 8.63: Qiagen Assays for Genetic Analysis
  • Table 8.64: Qiagen Pyrosequencing-Based Genetic Analysis Products
  • Table 8.65: Specifications and Features of Qiagen's QIAsymphony and QIAsymphony RGQ
  • Table 9.1: Drug Classes Investigated by 23andMe Using Genome Wide Association Studies
  • Table 9.2: Acquisition Profile of Affymetrix
  • Table 9.3: Genetic Applications of Axiom® Technology by Affymetrix
  • Table 9.4: Diversified Business Units of Affymetrix
  • Table 9.5: Affymetrix AgBio Microarray Portfolio
  • Table 9.6: BioMerieux Immunodiagnostic Product Portfolio
  • Table 9.7: BioMerieux Microbiology Product Portfolio
  • Table 9.8: BioMerieux Molecular Diagnostic Product Portfolio
  • Table 9.9: Celera (Quest Diagnostics) Historic Operating (Loss) (US$) - Laboratory Services and Products 2008-2010
  • Table 9.10: Diagnostic Test Product Categories Manufactured by BHL/Celera and Exclusively Distributed by Abbott
  • Table 9.11: Celldex Therapeutics R&D Expenses ($) 2010-2012
  • Table 9.12: Price Listing of Genelex Familial Genetic Tests
  • Table 9.13: Myriad - Core Business Decisions and Impact on Industry
  • Table 9.14: Future Test Portfolio of Myriad
  • Table 9.15: Nodality's Single Cell Network Profiling (SCNP) Technology as a Systems Based Biology Approach to Drug Discovery and Validation
  • Table 10.1: Drivers of the Oncogenic Biomarker Market
  • Table 10.2: Integration of Genomics and Biomarker Diagnostics into the Healthcare System
  • Table 10.3: Challenges of the Cancer Biomarker Market
Back to Top